Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability

Bibliography

• Zhou QT, Leung SS, Tang P, et al. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev. 2015;85:83–99.
   PubMed Web of Science ®Google Scholar
• Velkov T, Abdul Rahim N, Zhou QT, et al. Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Adv Drug Deliv Rev. 2015;85:65–82.
   PubMed Web of Science ®Google Scholar
• Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54(5):658–670.
   PubMed Web of Science ®Google Scholar
• Claus S, Weiler C, Schiewe J, et al. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86(1):1–6.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–360.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis. 2011;15(11):e753–e758.
   PubMed Web of Science ®Google Scholar
• Beinborn NA, Du J, Wiederhold NP, et al. Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur J Pharm Biopharm. 2012;81(3):600–608.
   PubMed Web of Science ®Google Scholar
• Sinha B, Mukherjee B, Pattnaik G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine. 2013;9(1):94–104.
   PubMed Web of Science ®Google Scholar
• Das PJ, Paul P, Mukherjee B, et al. Pulmonary delivery of voriconazole loaded nanoparticles providing a prolonged drug level in lungs: a promise for treating fungal infection. Mol Pharm. 2015;12(8):2651–2664.
   PubMed Web of Science ®Google Scholar
• Arora S, Haghi M, Loo CY, et al. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. Mol Pharm. 2015;12(6):2001–2009.
   PubMed Web of Science ®Google Scholar
• Arora S, Mahajan RR, Kushwah V, et al. Development of voriconazole loaded large porous particles for inhalation delivery: effect of surface forces on aerosolisation performance, assessment of in vitro safety potential and uptake by macrophages. RSC Adv. 2015;5(48):38030–38043.
   Web of Science ®Google Scholar
• Ong HX, Traini D, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv. 2013;10(9):1287–1302.
   PubMed Web of Science ®Google Scholar
• Draft F. Guidance for industry—metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. Chemistry, manufacturing, and controls documentation; 1998 Oct.
   Google Scholar
• Haghi M, Young PM, Traini D, et al. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm. 2010;36(10):1207–1214.
   PubMed Web of Science ®Google Scholar
• Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev. 2009;22(3):447–465.
   PubMed Web of Science ®Google Scholar
• Haghi M, Traini D, Young P. In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers. Pharm Res. 2014;31(7):1779–1787.
   PubMed Web of Science ®Google Scholar
• Kaur J, Muttil P, Verma RK, et al. A hand-held apparatus for “nose-only” exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci. 2008;34(1):56–65.
   PubMed Web of Science ®Google Scholar
• Verma RK, Germishuizen WA, Motheo MP, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57(2):1050–1052.
   PubMed Web of Science ®Google Scholar
• Verma RK, Agrawal AK, Singh AK, et al., et al. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis (Edinb). 2013;93(4):412–417.
   PubMed Web of Science ®Google Scholar
• Kumar Verma R, Mukker JK, Singh RS, et al. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. Mol Pharm. 2012;9(4):1011–1016.
   PubMed Web of Science ®Google Scholar
• Seville PC, Li HY, Learoyd TP. Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst. 2007;24(4):307–360.
   PubMed Web of Science ®Google Scholar
• Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release. 2011;152(3):370–375.
   PubMed Web of Science ®Google Scholar
• Gervelas C, Serandour AL, Geiger S, et al. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J Control Release. 2007;118(1):78–86.
   PubMed Web of Science ®Google Scholar
• Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110(1):130–140.
   PubMed Web of Science ®Google Scholar
• Chew NY, Shekunov BY, Tong HH, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005;94(10):2289–2300.
   PubMed Web of Science ®Google Scholar
• Benito M, Molins E, Contreras J. Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof. Google Patents 2012.
   Google Scholar
• Fiegel J, Garcia-Contreras L, Thomas M, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008;25(4):805–811.
   PubMed Web of Science ®Google Scholar
• Chan JG, Tyne AS, Pang A, et al. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm Res. 2014;31(5):1239–1253.
   PubMed Web of Science ®Google Scholar
• Tolman JA, Nelson NA, Bosselmann S, et al. Dose tolerability of chronically inhaled voriconazole solution in rodents. Int J Pharm. 2009;379(1):25–31.
   PubMed Web of Science ®Google Scholar
• Brain JD, Knudson DE, Sorokin SP, et al. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976;11(1):13–33.
   PubMed Web of Science ®Google Scholar
• Warheit DB, Brock WJ, Lee KP, et al. Comparative pulmonary toxicity inhalation and instillation studies with different TiO2 particle formulations: impact of surface treatments on particle toxicity. Toxicol Sci. 2005;88(2):514–524.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 1998;42(4):531–533.
   PubMed Web of Science ®Google Scholar
• Gavalda J, Martin MT, Lopez P, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 2005;49(7):3028–3030.
   PubMed Web of Science ®Google Scholar
• Tolman JA, Nelson NA, Son YJ, et al. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm. 2009;72(1):199–205.
   PubMed Web of Science ®Google Scholar